ralinepag

Sponsor United Therapeutics CORP · listed as UTHR

READOUT Phase 3 Confidence: medium Source: clinicaltrials

ralinepag is a clinical-stage drug asset sponsored by United Therapeutics CORP, listed as UTHR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT03683186. The asset is in Phase 3 and currently enrolling by invitation, studied in PAH.

Next catalyst

Event typeREADOUT

Expected date2026-12-31

As disclosedDec 2026

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT03683186

PhasePHASE3

StatusENROLLING_BY_INVITATION

Lead sponsorUnited Therapeutics

Listed asUTHR

Condition(s)PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseas…

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More UTHR catalysts